2003;362:759 66. 19. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-nepri- lysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993 1004. 20. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001 7. 21. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (CO- PERNICUS) study. Circulation. 2002;106:2194 9. 22. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240 327. 23. Eschalier R, McMurray JJV, Swedberg K, et al. Safety and effi- cacy of eplerenone in patients at high risk for hyperkalemia and/ or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIv- al Study in Heart Failure). J Am Coll Cardiol. 2013;62:1585 93. 24. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709 17. 25. Garg R, Yusuf S. Overview of randomized trials of angiotensin-con- verting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273:1450 6. 26. Woodard-Grice AV, Lucisano AC, Byrd JB, et al. Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymor- phism with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics. 2010;20:532 6. 27. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. ONTARGET Investigators. N Engl J Med. 2008;358:1547 59. 28. 